With the continuous emergence of novel FSP1 inhibitors and further elucidation of their specific roles in different tumor types and disease stages, combined with precise molecular subtyping and personalized combination therapies, targeting FSP1 is expected to become a powerful addition to future oncological healthcare, offering new advancements in the management of treatment-resistant cancers. Here, AIFM2 is linked to cancer.